The Financial Conduct Authority has eliminated the 7-day waiting period for connected research during UK equity IPOs, publishing the change in policy statement PS26/16 on 5 August 2026 (FCA). The regulator announced the move the day before, framing it as an effort to support UK listings (FCA).

Here is what that means in practice. When a company sells shares to the public for the first time (an IPO, or initial public offering), the banks managing the deal produce their own analyst research on the company. That research is called "connected" because it comes from analysts inside the underwriting syndicate — the group of investment banks running the offering. Independent analysts, who are not part of the deal, produce "unconnected" research. Under the now-scrapped rules, connected research had to sit on the shelf for seven days after unconnected research was published. The delay was part of an "equal information sharing" framework designed to keep all investors on the same footing.

The FCA's own consultation paper, CP26/14, acknowledged that the delay and the broader regime had "added unnecessary market risk and costs" (FCA). That consultation opened on 27 April 2026 (Reuters). PS26/16 finalises what CP26/14 proposed: removing the 7-day delay and easing the information-sharing constraints that govern how and when connected research reaches the market during an offering. The policy statement confirms the FCA's decision to proceed with those changes, stripping away a layer of process that issuers and syndicates argued created timing risk and friction without a matching benefit for investor protection.

The broader context here is a sustained regulatory push to make the UK listing regime more competitive. In July 2024, the FCA fast-tracked its largest overhaul of company listing rules in decades (Reuters). In January 2026, the regulator eased rules for companies raising capital, requiring a prospectus (a formal disclosure document for investors) only when issuing shares equal to 75% of existing capital (Reuters). By October 2025, the FCA was already considering further changes to accelerate IPO listings, including phasing out the two-stage filing system (Reuters). The removal of the 7-day connected research delay now follows as the latest concrete step in that trajectory.

The FCA has, however, flagged a structural caveat. Easing listing rules alone will not be sufficient to draw companies to London (Reuters). That admission matters for anyone assessing the likely impact of PS26/16. The IPO pipeline is a function of valuation differentials, liquidity depth, investor appetite, and macro conditions — not solely regulatory architecture. A faster research-release timeline reduces execution risk for the banks running the deal and may modestly shorten the IPO marketing window, but it does not resolve the fundamental question of whether companies see London as offering competitive pricing relative to alternative venues such as New York or Amsterdam.

For the banks and capital markets teams directly involved, the practical implication is straightforward. Connected research can now be published without the artificial delay that previously separated it from unconnected analyst output. This removes a sequencing constraint that complicated roadshow logistics — the multi-city marketing tour where company executives pitch investors — and created windows where syndicate analysts were effectively sidelined relative to independent coverage. Transaction teams will need to update their IPO execution playbooks and information barrier protocols to reflect the revised regime. Compliance teams should review PS26/16 in detail, as the policy statement supersedes the corresponding rules in the FCA Handbook that implemented the original equal information sharing requirements.

In my view, the regulatory question now is whether incremental adjustments like this one, layered on top of the 2024 listing reforms and the January 2026 capital-raising changes, compound into a materially more attractive IPO environment — or whether they represent marginal refinements to a regime whose competitiveness depends on factors the FCA itself acknowledges are beyond its remit. The honest answer is that rule changes can reduce friction, but they cannot manufacture the valuations, liquidity, and investor demand that ultimately determine where companies choose to list.